The phosphorylated BTK and PI3Kwill eventually lead to the activation of NF-kB, RAS and MAP kinases pathways [125,137], which will impair the anti-tumoral immunity, providing an antiapoptotic effect and enhancing the survival of CLL cells. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.